Repurposing live attenuated trivalent MMR vaccine as cost-effective cancer immunotherapy.
Zhang Y, Gabere M, Taylor MA, Simoes CC, Dumbauld C, Barro O, Tesfay MZ, Graham AL, Ferdous KU, Savenka AV, Chamcheu JC, Washam CL, Alkam D, Gies A, Byrum SD, Conti M, Post SR, Kelly T, Borad MJ, Cannon MJ, Basnakian A, Nagalo BM.
Zhang Y, et al. Among authors: gies a.
Front Oncol. 2022 Nov 9;12:1042250. doi: 10.3389/fonc.2022.1042250. eCollection 2022.
Front Oncol. 2022.
PMID: 36457491
Free PMC article.